SR Pharma achieves key technical breakthrough with its lyophilized liposomal-based siRNA formulation
SR Pharma plc has announced that it has made a technical breakthrough in the formulation of siRNA drugs, that enables its proprietary lyophilized (freeze dried) liposomally formulated siRNA (AtuRNAi) drugs to be stored at room temperature and reconstituted in one simple step, thus providing significant benefits, most notably extended shelf life and ease of administration.
To date, the AtuRNAi and liposomal components of AtuRNAi drugs have needed to be separately lyophilized (freeze-dried), reconstituted and then combined, in a multi-step process. The new SR Pharma process enables siRNA drugs pre-formulated as liposomal nanoparticles to be freeze-dried and then simply reconstituted with water immediately prior to patient administration with no additional preparation steps such as sonication being required.
"This is a significant breakthrough in the manufacture of siRNA drugs. A dry powder formulation extends the shelf-life and simplifies the distribution chain, with the one-step reconstitution process enhancing ease of administration. We will be applying this technology to the manufacture of our products as we take our siRNA drugs forward towards the clinic," said Dr Klaus Giese, CSO of SR Pharma.
Other news from the department research and development
These products might interest you
Eclipse by Wyatt Technology
FFF-MALS system for separation and characterization of macromolecules and nanoparticles
The latest and most innovative FFF system designed for highest usability, robustness and data quality
DynaPro Plate Reader III by Wyatt Technology
Screening of biopharmaceuticals and proteins with high-throughput dynamic light scattering (DLS)
Efficiently characterize your sample quality and stability from lead discovery to quality control
